Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinomaEmilio Bajetta, Roberto Buzzoni, Diego Cortinovis et al.|Cancer|2004Cited by 135
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i> -mutated metastatic colorectal cancer: the REVOLUTION study protocolAntonio Avallone, Alfredo Budillon, Maria Carmela Piccirillo et al.|Therapeutic Advances in Medical Oncology|2020Cited by 17
Phase III Study with FOLFIRI + Cetuximab Versus FOLFIRI + Cetuximab Followed by Cetuximab Alone in <i>RAS</i> and <i>BRAF</i> WT mCRCCarmine Pinto, Nicola Normanno, Armando Orlandi et al.|Future Oncology|2018Cited by 7
Preliminary Experience with High-Dose Cisplatin, Reduced Glutathione and Natural Interferon-α in Dacarbazine-Resistant Malignant MelanomaEmilio Bajetta, Antonio Cassata, Lorenza Rimassa et al.|Tumori Journal|1998Cited by 7
Optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC): the multicentre, randomized phase 3 study OBELICSAntonio Avallone, Maria Carmela Piccirillo, Guglielmo Nasti et al.|Annals of Oncology|2017Cited by 2